Is CYTO or DGRO a better dividend investment in 2026?

CYTO currently yields 666.67% with a 5% 5-year dividend growth rate. DGRO yields 2.13% with 9.5% growth. The better choice depends on your goal: CYTO offers higher current income.

What is the dividend yield difference between CYTO and DGRO?

CYTO has a forward dividend yield of 666.67% ($2.00/share annually). DGRO yields 2.13% ($1.47/share annually). The yield gap is 664.54 percentage points.

Home › Compare › CYTO vs DGRO

CYTO vs DGRO: Dividend Comparison 2026

CYTO yields 666.67% · DGRO yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CYTO wins by $608115.63M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CYTO

● Live price

666.67%

Share price

$0.30

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$608115.66M

Annual income

$469,561,018,816.25

Full CYTO calculator →

DGRO

iShares Core Dividend Growth ETF

● Live price

2.13%

Share price

$68.98

Annual div

$1.47

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.6K

Annual income

$239.96

Full DGRO calculator →

Portfolio growth — CYTO vs DGRO

📍 CYTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CYTO	DGRO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CYTO + DGRO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CYTO pays

DGRO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTO

Annual income on $10K today (after 15% tax)

$56,666.67/yr

After 10yr DRIP, annual income (after tax)

$399,126,865,993.81/yr

DGRO

Annual income on $10K today (after 15% tax)

$181.24/yr

After 10yr DRIP, annual income (after tax)

$203.97/yr

At 15% tax rate, CYTO beats the other by $399,126,865,789.85/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTO + DGRO for your $10,000?

CYTO: 50%DGRO: 50%

100% DGRO50/50100% CYTO

Portfolio after 10yr

$304057.84M

Annual income

$234,780,509,528.10/yr

Blended yield

77.22%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTO buys

DGRO buys

No recent congressional trades found for CYTO or DGRO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCYTODGRO

Forward yield	666.67% ✓	2.13%
Annual dividend / share	$2.00 ✓	$1.47
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$608115.66M ✓	$31.6K
Annual income after 10y	$469,561,018,816.25 ✓	$239.96
Total dividends collected	$596792.85M ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CYTO vs DGRO ($10,000, DRIP)

Year	CYTO Portfolio	CYTO Income/yr	DGRO Portfolio	DGRO Income/yr	Gap
1← crossover	$77,367	$66,666.67	$11,293	$213.22	+$66.1K → CYTO
2	$564,818	$482,035.31	$12,730	$217.32	+$552.1K → CYTO
3	$3,893,246	$3,288,890.67	$14,326	$221.10	+$3.88M → CYTO
4	$25,352,760	$21,186,987.16	$16,098	$224.56	+$25.34M → CYTO
5	$156,070,781	$128,943,327.59	$18,064	$227.74	+$156.05M → CYTO
6	$908,837,800	$741,842,064.29	$20,246	$230.65	+$908.82M → CYTO
7	$5,009,769,782	$4,037,313,336.56	$22,666	$233.30	+$5009.75M → CYTO
8	$26,159,339,258	$20,798,885,591.56	$25,349	$235.73	+$26159.31M → CYTO
9	$129,490,317,125	$101,499,824,118.87	$28,325	$237.94	+$129490.29M → CYTO
10	$608,115,658,140	$469,561,018,816.25	$31,624	$239.96	+$608115.63M → CYTO

CYTO vs DGRO: Complete Analysis 2026

CYTO — Stock

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Full CYTO Calculator →

DGRO — ETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →

📬

Get this CYTO vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTO vs SCHD CYTO vs JEPI CYTO vs O CYTO vs KO CYTO vs MAIN CYTO vs VIG CYTO vs NOBL CYTO vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.